Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Long-Term Debt Repayments (2017)

Viking Therapeutics (VKTX) has disclosed Long-Term Debt Repayments for 1 consecutive years, with $200000.0 as the latest value for Q3 2017.

  • Quarterly Long-Term Debt Repayments changed N/A to $200000.0 in Q3 2017 from the year-ago period, while the trailing twelve-month figure was $200000.0 through Dec 2018, down 33.33% year-over-year, with the annual reading at $3.8 million for FY2018, 4877.92% up from the prior year.
  • Long-Term Debt Repayments hit $200000.0 in Q3 2017 for Viking Therapeutics, up from $100000.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $200000.0 in Q3 2017 to a low of $100000.0 in Q2 2017.